Artificial skin compares well with autografts
This article was originally published in Clinica
Executive Summary
Artificial skin developed by US biotech company Ortec International has been successfully used to treat patients with epidermolysis bullosa, a rare genetic disease which causes the skin to become fragile and blister. Ortec's Composite Cultured Skin (CCS) performed as well as, or better than, grafts of the patient's own skin, an Australian paediatric surgeon reports in the British Journal of Plastic Surgery (December).